| scholarly article | Q13442814 |
| P2093 | author name string | R Chen | |
| S Ravichandran | |||
| G H Tan | |||
| A Apanovitch | |||
| A R Chacra | |||
| CV181-040 Investigators | |||
| J List | |||
| P2860 | cites work | Oral Antidiabetic Agents | Q22241436 |
| Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q24642503 | ||
| Translating the A1C assay into estimated average glucose values | Q24655833 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes | Q28262769 | ||
| DPP-4 inhibitors and their potential role in the management of type 2 diabetes | Q28271159 | ||
| Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes | Q29619192 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. | Q33864120 | ||
| Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis | Q34648377 | ||
| Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride | Q35783714 | ||
| Earlier intervention in type 2 diabetes: the case for achieving early and sustained glycaemic control. | Q36291021 | ||
| Mechanisms of beta-cell death in type 2 diabetes. | Q36321520 | ||
| Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. | Q36519973 | ||
| An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment. | Q36949127 | ||
| Glucose metabolism and hyperglycemia | Q37050752 | ||
| The burden of treatment failure in type 2 diabetes | Q40500624 | ||
| A model-based method for assessing insulin sensitivity from the oral glucose tolerance test | Q43566553 | ||
| Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus | Q44752163 | ||
| Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea | Q44956964 | ||
| Sulfonylurea induced beta-cell apoptosis in cultured human islets | Q45105959 | ||
| Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. | Q45974567 | ||
| The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy | Q46525578 | ||
| Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes | Q46691051 | ||
| Standards of medical care in diabetes--2008. | Q46828447 | ||
| Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study | Q46861155 | ||
| Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus | Q47265873 | ||
| Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. | Q51561183 | ||
| Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes. | Q51745195 | ||
| American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus | Q80572896 | ||
| P433 | issue | 9 | |
| P921 | main subject | patient | Q181600 |
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 1395-1406 | |
| P577 | publication date | 2009-07-15 | |
| P1433 | published in | International Journal of Clinical Practice | Q15758177 |
| P1476 | title | Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial | |
| P478 | volume | 63 |
| Q83176026 | A dipeptidyl peptidase-4 inhibitor for adults with type 2 diabetes |
| Q46100468 | A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea |
| Q35102138 | A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy |
| Q28282265 | A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes |
| Q28275281 | Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis |
| Q33732627 | Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials |
| Q26829445 | Assessment of pancreatic β-cell function: review of methods and clinical applications |
| Q37568863 | Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials |
| Q37517909 | Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum |
| Q59487668 | Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Chinese Subjects |
| Q35717211 | Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease |
| Q38468017 | Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus |
| Q35236019 | Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials |
| Q37346737 | Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin |
| Q33785197 | Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison |
| Q58701706 | Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis |
| Q38116766 | Complementing insulin therapy to achieve glycemic control |
| Q38154679 | Composite endpoints in trials of type-2 diabetes |
| Q35570938 | Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes |
| Q91638366 | DPP-4 Inhibition and the Path to Clinical Proof |
| Q40487459 | DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. |
| Q37638984 | DPP-4 inhibitors in clinical practice. |
| Q37612696 | Defining the importance of daily glycemic control and implications for type 2 diabetes management |
| Q35497064 | Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs |
| Q37995760 | Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes |
| Q41863397 | Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus |
| Q34214474 | Dipeptidyl Peptidase-4 (DPP-4) Inhibitors In the Management of Diabetes |
| Q38603506 | Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes |
| Q58829034 | Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials |
| Q35026483 | Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy |
| Q37778379 | Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions |
| Q36315963 | Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials |
| Q45985301 | Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes. |
| Q53354332 | Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. |
| Q39855313 | Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials |
| Q34454269 | Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetes |
| Q45545993 | Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes |
| Q42914097 | Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus |
| Q51365356 | Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial. |
| Q55262447 | Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis. |
| Q51292505 | Efficacy and safety of saxagliptin monotherapy or added to metformin in Chinese patients with type 2 diabetes mellitus: results from the 24-week, post-marketing SUNSHINE study. |
| Q33731748 | Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents |
| Q43462577 | Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis |
| Q34381281 | Emerging treatment options for type 2 diabetes |
| Q38645792 | Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin |
| Q36954446 | Encounter frequency and serum glucose level, blood pressure, and cholesterol level control in patients with diabetes mellitus |
| Q41958385 | Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers |
| Q38219482 | Evidence-based practice use of incretin-based therapy in the natural history of diabetes |
| Q38795046 | Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions |
| Q37835612 | Focus on incretin-based therapies: targeting the core defects of type 2 diabetes |
| Q37900151 | From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy |
| Q43116132 | GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus |
| Q33535235 | Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus |
| Q38264374 | Implications of incretin-based therapies on cardiovascular disease. |
| Q38479567 | Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes |
| Q37653125 | Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes |
| Q37781456 | Incretin-based Therapy in Chronic Kidney Disease |
| Q38140803 | Incretin-based therapies: focus on effects beyond glycemic control alone |
| Q37780914 | Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge |
| Q38036773 | Individualized treatment of type 2 diabetes mellitus using noninsulin agents: clinical considerations for the primary care physician |
| Q83470443 | Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin |
| Q57688763 | Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease |
| Q39157526 | Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit? |
| Q50876843 | Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes. |
| Q34154661 | Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥ 65 years) with type 2 diabetes |
| Q51367101 | Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. |
| Q38214060 | Management of unmet needs in type 2 diabetes mellitus: the role of incretin agents |
| Q37828337 | Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies |
| Q42058426 | New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin |
| Q38089327 | Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013. |
| Q34783302 | Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease |
| Q37446672 | Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies |
| Q38470357 | Pharmacokinetic study of saxagliptin in healthy Chinese subjects |
| Q38350347 | Pharmacologic treatment of type 2 diabetes: oral medications |
| Q37910902 | Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. |
| Q46071500 | Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials |
| Q51280718 | Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin. |
| Q37682555 | Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs |
| Q38026956 | Recent advances in incretin-based therapies |
| Q33886865 | Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes |
| Q33412360 | Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus |
| Q28259979 | Saxagliptin |
| Q37239303 | Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment |
| Q34078449 | Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis |
| Q51339320 | Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials. |
| Q38420531 | Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials |
| Q38753500 | Saxagliptin for the treatment of diabetes - a focus on safety |
| Q34128612 | Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data |
| Q37963451 | Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies |
| Q34620486 | Saxagliptin for type 2 diabetes |
| Q40524112 | Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA). |
| Q28278863 | Saxagliptin overview: special focus on safety and adverse effects |
| Q44896736 | Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial |
| Q38592351 | Saxagliptin: A Review in Type 2 Diabetes |
| Q36139126 | Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus |
| Q37784644 | Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus |
| Q35411329 | Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus |
| Q37973413 | Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU. |
| Q34239784 | Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus |
| Q42371758 | The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological Study |
| Q37977335 | The alpha-cell as target for type 2 diabetes therapy. |
| Q38134902 | The cardiovascular safety of incretin-based therapies: a review of the evidence |
| Q37992253 | The design of the liraglutide clinical trial programme |
| Q33866808 | The evolving place of incretin-based therapies in type 2 diabetes |
| Q38137027 | The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis |
| Q37641333 | The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus |
| Q38205588 | The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. |
| Q51365002 | The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. |
| Q38088195 | The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists |
| Q35760288 | The role of incretin therapy at different stages of diabetes |
| Q38024383 | The role of self-monitoring of blood glucose in glucagon-like peptide-1-based treatment approaches: a European expert recommendation |
| Q36785098 | Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus |
| Q42171281 | Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors |
| Q42818432 | Update on the latest family of oral drugs marketed for the treatment of type 2 diabetes: DPP-4 inhibitors. Contributions with respect to other families of oral antidiabetic agents |
| Q37857686 | Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin |
| Q36327126 | Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety |
Search more.